B.A. - 1990-94; University of Rochester, Rochester, NY; Biology and Religious Studies
M.D. - 1994-98; Case Western Reserve University, Cleveland, Ohio
1998-99 - Medical Internship: University Hospitals of Cleveland
1999-2001 - Residency, Internal Medicine: University Hospitals of Cleveland
2001-2003 - Fellowship, Hematology/Oncology: University Hospitals of Cleveland
2003-2004 - Chief Fellow, Hematology/Oncology: University Hospitals of Cleveland
Awards:
1994 - Irene Bush Steinbock Award for Human Relations
1994 - Highest Distinction in Religious Studies
1996 - Raymond Kiwala Excellence in Research Award
1998 - Alpha Omega Alpha Medical Honor Society
2002 - ASCO Molecular Therapeutics Symposium Travel Award Winner
2002 - Aventis Oncology Research Fellow Award
2003 - Murphy/Weisman Fellowship Award
2003 - Aventis Oncology Research Fellow Award
Case Comprehensive Cancer Center Activities:
Protocol Review and Monitoring Committee: Full Member
Genitorurinary Malignancy Team
Developmental Therapeutics Program: Phase I Team
Publications:
1. McHenry CR, Cooney MM, Slusarczyk SJ, and Khiyami A. Supraclavicular Lymphadenopathy: The Spectrum of Pathology and Evaluation by Fine-Needle Aspiration Biopsy. The American Surgeon. August 1999; 65:742-747.
2. Remick SC, Robertson K, Dowlati A, Cooney MM, Jeseberger J, Lewin J, Stambler B, Taylor A, Petros WP, Statford M, Young S, and Sherris D. for the CA4P Phase I Study Team. A phase I pharmacokinetic (PK) study of single dose intravenous (IV) Combretastatin A4 phosphate (CA4P) in patients (PTS) with advanced cancer. Clin. Cancer Res., 7 (suppl): 3733s, 2001. (Poster presentation.)
3. Dowlati A, Robertson K, Cooney MM, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin J, McCrae K, and Remick SC. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A4 phosphate (CA4P) on a single-dose intravenous schedule in patients with advanced cancer. Cancer Research 62, 3408-3416, June 15, 2002.
4. Cooney MM, Radivoyevitch T, Dowlati AD, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, Stambler B, and Scot C. Remick. Cardiovascular Safety Profile of Combretastatin A4 Phosphate (CA4P) in a Single-Dose Phase I Study in Patients with Advanced Cancer. Clin Cancer Research Jan 1; 10(1) 96-100, 2004.
5. Cooney, MM, Remick SR, and Nicolas Vogelzang. A Medical Oncologist’s Approach for Immnotherapy for Advanced Renal Tumors: Is Nephrectomy Indicated? Current Urology Reports Feb; 5(1) 19-24, 2004.
6. Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingall ST, Dowlati A, Overmoyer B, McCrae K, Ksenich P, Lavertu P, Ivy P, Hoppel C, and Scot C. Remick. A Phase IB Clinical and Pharmacokinetic Study of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck. Accepted for publication, Cancer Chemotherapy and Pharmacology.
7. Cooney MM, Radivoyevitch, Dowlati A, Overmoyer B, Levitan N, Robertson K, Stambler B, and Scot C. Remick. Reply to: Letter to the Editor, Submitted by Varterasian M, et al. Regarding “Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer.” Clin Cancer Research. Accepted for publication.
8. Cooney MM and Remick SC. Is nephrectomy indicated in advanced kidney cancer? Journal of Urology Review. Accepted for Publication.
9. Cooney MM, Remick SC, Vogelzang NJ. Novel agents for the treatment of advanced kidney cancer. Accepted for publication.
10. Cooney MM and Remick SC. Combretastatin A4 and Derivatives: Novel Vascular Targeting Agents. Current Urology Reports. Accepted for Publication.
Poster Presentations:
1. Cooney MM, McHenry CR, Slusarczyk SJ, and Khiyami A. Supraclavicular Lymphadenopathy: The Spectrum of Pathology and Evaluation by Fine-Needle Aspiration Biopsy. Case Western Reserve University, Cleveland, OH. Midwest Surgical Association Meeting, Mackinac Island, Michigan August 16-18, 1998.
2. Cooney MM, Dowlati A, Robertson K, Levine S, DeCaro K, et al. Cardiovascular Safety Profile of Combretastatin A4 Phosphate (CA4P) in a Single-Dose Phase I Pharmacokinetic Study in Patients with Advanced Cancer. Case Western Reserve University, University Hospitals of Cleveland. American Society of Clinical Oncology Molecular Therapeutics Symposium, Coronado California, November 7-10, 2002.
Abstracts:
1. Cooney MM, Brophey S, Ingalls S, Hoppel C, Krishnamurthi S, Dowlati A, Overmoyer B, McPeak J, Brell J, Remick SC. Phase I pharmacokinetic trial of thalidomide and docetaxel: a regimen based on anti-angiogenic therapeutic principals. Case Comprehensive Cancer Center, University Hospitals of Cleveland, Cleveland,OH.. PROC ASCO, New Orleans June 2004, Abstract 3135.
Workshop and Conference Attendance:
1. AACR/ASCO 2002 Educational Workshop: Methods in Clinical Cancer Research. July 27-August 2, 2002. Vail Cascade Resort. Vail, Colorado.
2. Cancer Education Consortium: Clinical Pharmacology of Anticancer Agents.October 18-22, 2002. Lansdowne Conference Center, Leesburg, Virginia.
3. Anneberg Center for Health Sciences: Emerging Perspectives in Hematologic and Solid Cancers: Advancing Clinical Dialogue Through Mentorship. May 15-17, 2003. Anneberg Center for Health Sciences, Palm Springs, California
Invited Speaker Appearances:
1. Case Western Reserve University and University Hospitals of Cleveland, 2nd Annual Urolgoy Conference. Presentation entitled “Treatment of metasatic prostate cancer.” February 28, 2004. Cleveland, Ohio.
2. Northern Ohio Nurse Practicioner Annual Conference. Presentation entitled: “Cancer screening for the primary care provider.” April 30, 2004. Cleveland, Ohio.
Peer Journal Review:
I have reviewed manuscripts for the following journals:
Cancer Chemotherapy and Pharmacology
Clinical Cancer Research
Investigator Initiated Clinical Trials:
1. CASE 2004: Phase II Pharmacodynamic Trial of AZD2171 in advanced renal cancer. Principal Investigator). Sponsors: Case Case Comprehensive Cancer Center. Submitted to CTEP.
2. Case 2804: (CTEP Approaved funding 12/03) A Phase II randomized trial of BAY 43-9006, a novel Raf kinase inhibitor, versus BAY 43-9006 plus paclitaxel/carboplatin in women with recurrent platinum sensitive ovarian or peritoneal cancer. (Co-PI). Sponsors: Case Comprehensive Cancer Center, CTEP.
3. Case 2Y04: Phase I Trial of Daily CC-5013 (Revlimid) and Docetaxel Given Every Three Weeks. (Principal Investigator). Sponsors: Case Comprehensive Cancer Center, Aventis Pharmaceuticals, and Celgene Corporation.
4. CWRU 1301: Phase I Study of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination with Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck. (Co-Investigator). Sponsors: Case Comprehensive Cancer Center, CTEP (IN-54934) and Aventis Pharmaceuticals.
5. CWRU 4Y01: Phase I Pharmacodynamic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Priciniples. (Co-PI). Sponsors: Case Comprehensive Cancer Center, Celegene Corporation and Aventis Pharmaceuticals.
6. CWRU 1502: Phase II Study using Oral Thalidomide in Extensive Stage Small Cell Lung Cancer. (Co-PI). Sponsors: Case Comprehensive Cancer Center, and Celgene Corporation.
7. ICC 2302: Phase II Trial of Combretastatin A-4 Phosphate (CA4P) in Advanced Anaplastic Carcinoma of the thyroid. (Co-Investigator). Sponsors: Case Comprehensive Cancer Center, and Oxigene Corporation.
8. ICC 3302: Phase IB/II Trial of Combined Modality CombretastatinA-4 Phosphate (CA4P)-based Therapy for Patients with Newly Diagnosed Anaplastic Thyroid Cancer (Co-Investigator). Sponsors: Case Comprehensive Cancer Center, and Oxigene Corporation.
Department of Medicine|
11100 Euclid Avenue| Cleveland, Ohio 44106
